Catalyst Crew Technologies Develops NeuroAI Platform for Neurological Analysis and Risk Prediction

Catalyst Crew Technologies Corp. has announced the development of NeuroAI, an artificial intelligence-enabled module designed to support neurological analysis and predictive risk modeling. The platform is intended to assist healthcare providers in analyzing neurological data and identifying potential clinical risks through artificial intelligence-driven analytics. Its proposed capabilities include early detection of neurological abnormalities, predictive modeling of cerebrovascular events, and AI-assisted analysis of brain imaging and cognitive data.

The platform is being developed to integrate multiple data inputs, including magnetic resonance imaging (MRI), electroencephalograms (EEG), cognitive assessments, and patient-specific data, in order to generate structured outputs intended to support clinical review and care coordination. NeuroAI forms part of the Company's broader artificial intelligence healthcare platform and is expected to function as a specialized module within Catalyst Crew's digital health ecosystem. Management believes that modular AI systems, such as NeuroAI, may support scalable deployment across telehealth services, remote monitoring, and technology-enabled healthcare delivery environments.

The Company intends to integrate NeuroAI across its existing and planned healthcare infrastructure initiatives, including its healthcare services coordination platform. As development progresses, NeuroAI is expected to support data-driven insights and clinical decision-support capabilities across neurological care pathways. Catalyst Crew Technologies intends to prioritize market development in Latin America, where the Company believes artificial intelligence-enabled healthcare technologies may help expand access to neurological evaluation tools, support early identification of conditions, and improve healthcare system efficiency.

Dr. Kevin Rodan Levy, Chief Executive Officer of Catalyst Crew Technologies Corp., stated that advancements in artificial intelligence present new opportunities to assist in the early identification and monitoring of neurological conditions. NeuroAI is part of the broader strategy to develop integrated, scalable healthcare technologies that can support medical professionals and improve patient care. The Company intends to continue developing and refining NeuroAI and its broader healthcare technology platform while evaluating opportunities for pilot programs, strategic partnerships, and phased market deployment.

For more information, please visit https://catalystcrewai.com or review the Company's filings with the U.S. Securities and Exchange Commission at https://www.sec.gov. The Company is a development-stage enterprise and has not generated revenues from its newly announced business direction. There can be no assurance that the Company will successfully implement its business plan, complete acquisitions, secure financing, obtain regulatory approvals, or generate revenues. Any investment decision should be made solely on the basis of information contained in the Company's filings with the U.S. Securities and Exchange Commission and other publicly available documents.